Sacituzumab Govitecan Demonstrates Efficacy in HR+/HER2- Metastatic Breast Cancer
• Sacituzumab govitecan (SG) significantly improved progression-free survival (PFS) compared to chemotherapy in patients with HR+/HER2- metastatic breast cancer.
• The phase 3 EVER-132-002 trial included patients who had received two to four prior chemotherapy regimens, showing SG's benefit in heavily pre-treated populations.
• SG demonstrated a manageable safety profile, supporting its potential as a valuable treatment option for this patient population in regions including mainland China, Republic of Korea and Taiwan.
• The study's findings contribute to addressing the unmet need for effective therapies in HR+/HER2- metastatic breast cancer, particularly after multiple lines of treatment.
© Copyright 2025. All Rights Reserved by MedPath